Pfizer To Expand In China To Cushion Lipitor Patent Expiration
This article was originally published in PharmAsia News
Pfizer plans to expand its operations in China as part of a cost-cutting response to the looming lapse of the patent on its Lipitor (atorvastatin) anti-cholesterol statin. CFO Frank D'Amelio said Pfizer plans to outsource more of its manufacturing operations in preparation for generic competition to its best-selling drug. The patent expires in November 2011. D'Amelio said Pfizer also plans to expand the number of drugs it pursues in other areas. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.